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thyroid gland, parotids and bone marrow according to and FLT ((18)F-
fluoro-thymidine)-PET images, before and during the treatment.  
Materials and Methods: Patients with advanced, inoperable 
oropharynx and oral cavity cancer were treated with chemoradiation. 
(RTCT). The dose of 70 Gy in 35 fractions was delivered concurrently 
with three courses of cisplatin(100mg/m2) provided on the 1st, 22nd 
and 43rd day of treatment. FLT PET/CT was performed a week before 
and then on 7th and 14th day of treatment, corresponding to a dose of 
14 and 28 Gy respectively. The whole imaging was performed while 
ensuring the same mode of patient’s immobilization i.e. individual 
thermoplastic mask. Volumes of thyroid gland, both parotids and 
cervical vertebrae were measured on CT scans obtained before 
treatment and at the FLT PET time point. CT and PET images were 
matched to assess the level of proliferation at the organ of interest. 
SUV mean was used to quantify differences in proliferation level. 
Thyroid hormones level were assayed prior to the treatment and then, 
weekly during the treatment followed by the one month after 
completion of the treatment evaluation to assess the level of 
functional changes. For statistical calculation Pearson’s correlation 
coefficient and Wilcoxon Matched Pair Test were used, for alpha=0.5  
Results: Both volume and FLT SUVmean of the thyroid gland 
decreased during treatment (p= 0.009 and 0.03 respectively). Changes 
of volume of thyroid gland correlated with the decrease of FLT 
SUVmean in the first week of treatment. (R=0.90) Thyroid hormones 
levels fluctuate during and after chemoradiation. Thyroid-stimulating 
hormone (TSH) level measured a month after RTCT negatively 
correlates with FLT SUVmean in the first week of treatment (R=0.89) 
Volume of homolateral and contralateral parotids decreases 
significantly during first week of treatment (p=0.003 and 0.01 
respectively). Degree of parotid volume change depends on its initial 
volume before treatment (R=0.7). FLT SUVmean reduction in bone 
marrow after first week of treatment reflects depletion of 
proliferating cells (p=0.002) 
Conclusions: Morphologica land functional changes in head and neck 
organs can be estimate during RTCT. Assessment of the volumetric 
and metabolic changes of certain organ at risk during treatment could 
be a predictor of their future function and can help in further 
individualization of treatment planning.  
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Purpose/Objective: Besides basic measurements as SUVmax, SUVmean or 
tumor volume derived from 18F-FDG PET scans, more advanced 
quantitative imaging features are increasingly investigated for 
treatment monitoring and outcome prediction. This is within the 
context of Radiomics: extracting and mining a large number of 
quantitative features from medical images, where it is hypothesized 
that it will improve tumor characterization and outcome prediction. 
However, in order to use these features for future prognostic and 
predictive models, it is required that they are reliable. This study 
therefore aims to assess the repeatability of Radiomics features 
derived from PET images in NSCLC. 
Materials and Methods: Eleven NSCLC patients were included 
retrospectively in this study. All patients underwent two baseline 18F-
FDG PET scans within a one day interval, before any treatment was 
delivered. 60-min. emission scans were obtained on an ECAT EXACT 
HR+ scanner (Siemens/CTI) in 2D mode and reconstructed using 
OSEM2Dx16s, followed by 5mm FWHM Gaussian post-smoothing. Per 
patient, all lesions with adequate uptake and contrast were identified 
and delineated by applying one of four predefined thresholds of the 
maximum uptake value within the tumor (41%, 50% and 70% corrected 
for local background and 50% uncorrected for background) (figure 1). 
The extracted image features comprised 15 first-order statistics, 33 
textural features derived from gray level co-occurrence and gray level 
run-length matrices, 51 metabolic descriptors of the intensity volume 
histogram (IVH) and 7 features describing the shape and size of the 
delineated VOI. Repeatability for every extracted image feature was 
assessed with the intraclass correlation (ICC) and the coefficient of 
repeatability (COR), expressed as a percentage of the sample 
estimated reference range. 
 
 
Results: 32 lesions were selected for analysis. Repeatability analysis 
of shape and size characteristics of the defined VOIs revealed a good 
agreement between the two baseline scans, with ICC and COR values 
ranging from 0.94-1 and 2.8%-17.1% respectively for all 7 features. 
13/15 of the considered first order statistics showed high repeatability 
with an ICC between 0.77–0.96 and a COR between 12.3%-38.6%. An 
ICC between 0.7-1 and a COR of 3.6%-37.2% was found for 28/33 
textural features. From the IVH features, 40/51 were highly 
repeatable with an ICC and a COR of 0.78-1 and 2.8%-31.4% 
respectively. The overall results are summarized in table 1. 
 
  
Conclusions: The results of this study indicate that the majority of 
assessed PET image features are highly repeatable and suggest that 
further analysis of these parameters may be warranted for treatment 
monitoring and outcome prediction in NSCLC. 
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Purpose/Objective: To test the hypothesis that cardiac comorbidity 
before the start of (chemo)radiotherapy (RCHT) is associated with an 
increased risk of radiation induced lung toxicity (RILT) in lung cancer 
patients. 
Materials and Methods: A prospective cohort of 149 non-resectable 
lung cancer patients with locoregional disease was studied, that was 
treated with definite (chemo)radiotherapy between 2007 and 2011 
(ClinicalTrials.gov Identifiers: NCT00572325 and NCT00573040). Prior 
to oncological therapy, 42 (28.2%) patients had recorded treatment of 
cardiovascular pathologies at a cardiology department and 44 (29.5%) 
developed RILT, measured by dyspnea grade ≥ 2 according to CTCv.3.0 
within 6 months after radiotherapy. 
Results: Half of the patients with cardiac comorbidity (21/42) 
presented with dyspnea grade ≥ 2 within 6 months after RCHT, 
compared to 21.5% (23/107) of those without such comorbidity. The 
odds ratio of RILT for a patient with a cardiac comorbidity was 3.65 
(p-value < 0.001, 95% CI: 1.70 – 7.81, see Figure 1). Conversely, for 
common factors associated with RILT, such as mean lung dose, age, 
smoking status, World Health Organization performance status and 
Forced Expiratory Volume in 1 second no significant associations were 
